How JAK Inhibitors Work to Treat Autoimmune Diseases

JAK inhibitors are a class of drugs that block enzymes called Janus kinases, which act as relay switches inside cells for dozens of immune and inflammatory signals. By interrupting these signals, JAK inhibitors can dial down overactive immune responses in conditions ranging from rheumatoid arthritis to eczema to certain blood cancers. They come as pills rather than injections, which sets them apart from the biologic drugs that dominated autoimmune treatment for two decades. But that convenience comes with trade-offs, particularly around cardiovascular and blood-clot risks, that have shaped how doctors prescribe them and who gets them first.

How JAK Inhibitors Work

More than 50 cytokines, the chemical messengers that coordinate immune activity, rely on a signaling chain called the JAK-STAT pathway to get their instructions inside a cell.¹ When a cytokine latches onto a receptor on a cell’s surface, Janus kinases (JAK1, JAK2, JAK3, and TYK2) physically pair up, activate each other, and then switch on STAT proteins that travel into the nucleus and flip specific genes on or off.² In diseases like rheumatoid arthritis or ulcerative colitis, this pathway runs too hot, pumping out inflammation continuously. JAK inhibitors slip into the energy-docking site on the kinase and block it from firing.

The challenge is that all four JAK family members share a very similar shape at the site where these drugs bind, making it hard to block one without hitting the others.³ Tofacitinib, for instance, can interact with all four JAKs through hydrogen bonds and other molecular forces at the same docking site.⁴ That broad reach is a double-edged sword: it can quiet inflammation effectively, but it also suppresses JAK-dependent pathways the body actually needs, like those governing blood cell production and parts of the immune defense against viruses.

Which Diseases They Treat

By 2022, eleven JAK inhibitors had been approved somewhere in the world, covering an expanding list of conditions.⁵ The major categories break down roughly as follows:

Inflammatory arthritis: Tofacitinib, baricitinib, upadacitinib, filgotinib, and peficitinib are used for rheumatoid arthritis. Tofacitinib and upadacitinib are also approved for psoriatic arthritis and ankylosing spondylitis.
Inflammatory bowel disease: Tofacitinib is approved for ulcerative colitis, and upadacitinib has gained approvals for both ulcerative colitis and Crohn’s disease.
Skin conditions: Baricitinib and ritlecitinib are approved for alopecia areata. Abrocitinib, baricitinib, and upadacitinib are approved for atopic dermatitis. Topical ruxolitinib is approved for vitiligo.
Blood cancers: Ruxolitinib treats myelofibrosis and polycythemia vera. Fedratinib and pacritinib also target myelofibrosis.
Veterinary medicine: Oclacitinib (Apoquel) is used in dogs for allergic dermatitis.

That breadth reflects how central the JAK-STAT pathway is to the immune system. If a disease involves runaway cytokine signaling, there is a reasonable chance someone is testing a JAK inhibitor against it.

Rheumatoid Arthritis and How They Compare to Biologics

In rheumatoid arthritis, JAK inhibitors are generally positioned after conventional drugs like methotrexate have failed. A large international registry study covering nearly 32,000 patients found that people on JAK inhibitors were actually less likely to stop treatment because it wasn’t working compared to those on TNF inhibitors, one of the most common biologic classes.⁶ Disease activity scores at one year were similar between the two classes. However, people on JAK inhibitors were somewhat more likely to discontinue due to side effects.

A meta-analysis comparing the two classes head-to-head found that JAK inhibitors produced a small but statistically meaningful improvement in physical function scores over TNF inhibitors.⁷ The practical difference is modest, and for many patients the choice comes down to the side-effect profile and the route of administration. Biologics require injection or infusion, usually every one to four weeks. JAK inhibitors are daily pills you take at home, which many patients find easier to manage.⁸ Patients in survey studies also appreciated that JAK inhibitors leave the body quickly. If an infection develops, you simply stop taking the pill and the drug clears within hours, whereas some biologics linger in the body for weeks.

Psoriatic Arthritis and Spinal Arthritis

JAK inhibitors have earned a foothold in other types of inflammatory arthritis as well. In psoriatic arthritis, a meta-analysis of five randomized trials involving roughly 3,300 patients found that people on a JAK inhibitor were nearly four times as likely to achieve at least a 20% improvement in joint symptoms compared to placebo.⁹ That level of response is comparable to what biologic drugs achieve in the same condition.¹⁰

For ankylosing spondylitis, the evidence is a step behind, but pooled data from clinical trials show that JAK inhibitors improve disease symptoms within about three months and, helpfully for patients with psoriatic arthritis, also improve the skin lesions of psoriasis alongside joint inflammation.¹¹ That two-for-one effect is valuable because many patients with psoriatic arthritis deal with painful joints and itchy, flaking skin at the same time.

Gut Inflammation and the Crohn’s Disease Puzzle

In ulcerative colitis, JAK inhibitors have performed well. A meta-analysis found they tripled the chances of achieving clinical remission compared to placebo and were even more effective at healing the intestinal lining, with a more than fivefold increase in mucosal healing rates.¹² Tofacitinib was the first to gain approval here, and upadacitinib has since followed.

Crohn’s disease has been a tougher nut to crack. Tofacitinib, despite working in ulcerative colitis, failed its primary goals in Crohn’s trials and its development for that condition was shelved.¹³ But the more selective JAK1 inhibitors, filgotinib and upadacitinib, fared better. In an early real-world study, roughly 70% of Crohn’s patients on upadacitinib reached clinical remission by eight weeks, with benefits showing up as early as week two.¹⁴ The lesson seems to be that selectivity matters. A broad JAK inhibitor may suppress too many pathways in Crohn’s, some of which the gut actually needs, while a more targeted one hits the inflammatory signals without as much collateral damage.

Skin Conditions and Hair Loss

JAK inhibitors have become an important option for alopecia areata, an autoimmune condition where the immune system attacks hair follicles. The drugs block the interferon-gamma signaling that drives the immune assault on follicles, allowing hair to regrow.¹⁵ In one of the earlier clinical studies, about a third of patients on tofacitinib saw at least a 50% improvement in scalp hair coverage.¹⁶ People with patchy hair loss responded better than those who had lost all their scalp or body hair, and shorter disease duration predicted a better outcome. Baricitinib and ritlecitinib have since received regulatory approvals specifically for alopecia areata, giving patients who previously had almost no FDA-approved options a real treatment pathway.¹⁷

Vitiligo, another autoimmune skin condition where pigment-producing cells are destroyed, has also responded to JAK inhibition. Here the approach is topical rather than oral. Ruxolitinib cream delivers the drug directly into the skin where it blocks the inflammatory pathway, achieving high concentrations in the epidermis and dermis while barely registering in the bloodstream.¹⁸ That topical approach sidesteps most of the systemic side effects that concern doctors about oral JAK inhibitors, and it was approved by the FDA as the first drug specifically indicated for non-segmental vitiligo in adults.

Blood Cancers

Ruxolitinib was actually the first JAK inhibitor to reach the market, approved in 2011 not for an autoimmune disease but for myelofibrosis, a blood cancer in which the bone marrow produces scar tissue and stops making blood cells properly. In the pivotal trial, about 42% of patients on ruxolitinib achieved a meaningful reduction in spleen size, compared to less than 1% on placebo. Nearly half the ruxolitinib group saw their symptom burden drop by 50% or more, and deaths were cut roughly in half over the trial period.¹⁹ In myelofibrosis, a specific mutation causes the JAK2 enzyme to be stuck in the “on” position, driving uncontrolled blood cell production and inflammation. Ruxolitinib targets that directly. Fedratinib and pacritinib later joined ruxolitinib as options for patients who can’t tolerate it or whose disease progresses on it.

The Safety Trade-Offs

The biggest cloud over JAK inhibitors came from a large, long-running safety trial called ORAL Surveillance. Over a median of four years, patients with rheumatoid arthritis on tofacitinib experienced heart attacks, strokes, and cancers at somewhat higher rates than those on a TNF inhibitor. The hazard ratio was about 1.33 for major cardiovascular events and about 1.48 for cancers.²⁰ The cancer signal grew more apparent after roughly 18 months of treatment, particularly for lung cancer and at the higher 10 mg twice-daily dose.²¹

Blood clots are another concern. A Swedish study of rheumatoid arthritis patients found that the rate of venous blood clots on JAK inhibitors was roughly double that on TNF inhibitors, with the risk of pulmonary embolism specifically being about three times higher.²² A global cohort study in atopic dermatitis found a similar pattern when comparing JAK inhibitors to dupilumab, with roughly eight to nine additional cases of pulmonary embolism or deep vein thrombosis per 1,000 patients starting JAK inhibitors.²³

These findings led regulators to add boxed warnings and, in most treatment guidelines, to position JAK inhibitors after biologic therapies rather than alongside them. The people at highest risk tend to be older, smokers, or those with a prior history of cardiovascular problems or blood clots. For younger patients without those risk factors, the absolute risk increase is small. But it is real, and it is the main reason JAK inhibitors are not first-line therapy in most autoimmune conditions despite their oral convenience.

Infection Risk, Especially Shingles

Because JAK inhibitors dampen parts of the immune system, infections are a predictable concern. The standout here is herpes zoster, or shingles. A network meta-analysis across multiple immune-mediated diseases found that several JAK inhibitors at their standard or higher doses significantly increased the risk of shingles compared to placebo. The effect was most pronounced in rheumatoid arthritis patients, where higher doses of baricitinib, peficitinib, and upadacitinib all carried elevated odds.²⁴ Most guidelines now recommend that patients receive the recombinant shingles vaccine before starting a JAK inhibitor, ideally at least two to four weeks beforehand, to build immunity while the immune system is still fully functional.

TYK2 Inhibitors and the Next Generation

Much of the safety concern with first-generation JAK inhibitors stems from the fact that they block multiple JAK family members, suppressing beneficial pathways alongside harmful ones. One way around that is to avoid the active site entirely. Deucravacitinib, approved for psoriasis, targets a completely different region of TYK2, the regulatory pseudokinase domain, rather than the catalytic site where older drugs bind.²⁵ Because this regulatory domain looks structurally distinct from JAK1, JAK2, and JAK3, deucravacitinib achieves selectivity that was essentially impossible with active-site inhibitors.²⁶ Early clinical data suggest this selectivity translates into fewer of the blood count changes and lipid elevations seen with broader JAK inhibitors, though long-term safety comparisons are still in progress.²⁷

If this approach pans out in longer trials, it could redefine where JAK-pathway drugs sit in treatment sequences, potentially moving them earlier because the safety profile no longer demands the caution that current drugs do.

Off-Target Effects and Why They Are Hard to Predict

Part of what makes JAK inhibitor safety complicated is that these drugs don’t only hit JAKs. Computer-based profiling of baricitinib and tofacitinib identified a total of 99 potential off-target binding interactions. Among those, 17 involved proteins connected to blood clotting or viral defense. When researchers tested the ones they could, several showed genuine binding at drug-relevant concentrations.²⁸ This kind of off-target activity may explain why the blood-clot risk and the shingles risk aren’t simply proportional to how strongly a drug blocks a given JAK isoform. The side-effect profile is shaped by a complicated web of unintended interactions that vary from drug to drug.

COVID-19 and Cytokine Storms

An unexpected chapter in the JAK inhibitor story unfolded during the COVID-19 pandemic. Severe COVID often involved a “cytokine storm” in which the body’s immune system attacks its own tissues, and researchers recognized that JAK inhibitors could potentially cool that response. Baricitinib proved effective, reducing plasma levels of IL-1β, IL-6, and TNF-α within seven days in patients with severe disease.²⁹ The drug received emergency use authorization in several countries and became part of standard treatment protocols for hospitalized COVID patients. It was a useful proof-of-concept that JAK inhibitors can be employed acutely, not just chronically, when the right inflammatory cascade is involved.

Cost and the Practical Case for Oral Therapy

Biologic drugs are expensive, and so are JAK inhibitors, but the cost comparison has some nuance. A modeling study in rheumatoid arthritis found that using baricitinib in a treat-to-target strategy produced lower costs and better quality-of-life outcomes over five years compared to a biologic-based strategy.³⁰ In ulcerative colitis in Japan, tofacitinib was more cost-effective than several biologics including vedolizumab, infliximab, and golimumab as a first-line advanced therapy.³¹ Beyond the sticker price, oral pills also eliminate the costs associated with infusion centers, nurse visits for injections, cold-chain storage, and the time patients spend traveling for treatment. These indirect savings can be substantial, particularly in rural areas or countries with limited infusion infrastructure.

JAK Inhibitors for Dogs

Veterinarians may have been the earliest mass adopters of JAK inhibition. Oclacitinib (brand name Apoquel) was approved for canine allergic dermatitis and quickly became one of the most prescribed veterinary drugs in the world. In clinical trials, dogs on oclacitinib went from “severe itching” to “very mild itching” within a week, and the reduction in itching was already apparent after a single day of treatment.³² In a randomized trial, oclacitinib-treated dogs showed roughly a 62% reduction in itching scores by day 7 compared to about 7% in placebo dogs, and dermatologist-assessed skin lesion scores improved by nearly 50% by two weeks.³³ The drug’s speed of onset was a major selling point. For pet owners who had cycled through antihistamines, steroids, and special diets, a pill that worked within 24 hours felt transformative.

New Delivery Methods Under Development

A significant chunk of current research aims to keep the benefits of JAK inhibitors while avoiding the systemic exposure that causes most side effects. One group is developing baricitinib as a topical nanoemulgel for atopic dermatitis, aiming to deliver the drug directly to inflamed skin and avoid the off-target effects of oral dosing.³⁴ Another team engineered protein-based nanoparticles that encapsulate upadacitinib for topical application over arthritic joints. In a mouse arthritis model, these nanoparticles reduced joint inflammation with no detectable systemic toxicity.³⁵ These are still early-stage concepts, but they represent a logical trajectory: the drugs work, the concern is where they go in the body, so put them only where they’re needed.

Predicting Who Will Respond

One frustration with JAK inhibitors is that doctors can’t reliably predict which patients will benefit most. Research into biomarkers is underway but still inconclusive. A gene expression study of rheumatoid arthritis patients on JAK inhibitors identified 13 genes whose activity patterns partially separated responders from non-responders, though the separation wasn’t clean enough to use clinically.³⁶ A pharmacogenetic study found that a specific variant of the TNFRSF10A gene was associated with roughly a fourfold higher likelihood of achieving remission on JAK inhibitor therapy.³⁷ That’s an intriguing signal, but it comes from a single study and needs replication before anyone would base treatment decisions on it. For now, prescribing JAK inhibitors is still largely empirical: try it, see if it works within a few months, and switch if it doesn’t.